Update on the treatment of focal segmental glomerulosclerosis in renal transplantation

doi:10.5500/wjt.v6.i1.54

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11980)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

1024

WORD

444

HTML

6011

Figures (1-1)

159

Tables (1-1)

147

Sum=7785

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

650

Download

1282

Sum=1932

Publishing Process of This Article

Item

Count

Browse

962

Download

1301

Sum=2263

Mar 24, 2016 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Mar 24, 2016; 6(1): 54-68
Published online Mar 24, 2016. doi: 10.5500/wjt.v6.i1.54

Open in New Tab Full Size Figure Download Figure

Figure 1 Evolution of the therapeutic approaches for focal segmental glomerulosclerosis recurrence and related recent perspectives. The various treatments and their mechanisms are represented by the star shapes. CyA: Cyclosporine; PE: Plasma exchange; MMF: Mycophenolate mofetil; suPAR: Soluble form of the urokinase type plasminogen activator receptor; CYC: Cyclophosphamide; RTX: Rituximab^®; IA: Immuno-adsorption; Synpo: Synaptopodine; SMLPD-3b: Sphingomyelin-phosphodiesterase-acid-like-3b protein. Note: Steroids also regulate the podocyte activity of stabilizing the actin cytoskeleton, preserving glomerular permeselectivity, and directly reducing apoptosis via the PI3K/Akt signaling pathway.

Citation: Messina M, Gallo E, Mella A, Pagani F, Biancone L. Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World J Transplant 2016; 6(1): 54-68
URL: https://www.wjgnet.com/2220-3230/full/v6/i1/54.htm
DOI: https://dx.doi.org/10.5500/wjt.v6.i1.54